{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:36:22Z","timestamp":1767969382833,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007920","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T00:00:00Z","timestamp":1380672000000}}],"reference-count":65,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007920.pub2","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T12:58:29Z","timestamp":1380718709000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anti-vascular endothelial growth factor for neovascular glaucoma"],"prefix":"10.1002","author":[{"given":"Arathi","family":"Simha","sequence":"first","affiliation":[{"name":"Christian Medical College; Department of Ophthalmology; Vellore India 632001"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Braganza","sequence":"additional","affiliation":[{"name":"Christian Medical College; Department of Ophthalmology; Vellore India 632001"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lekha","family":"Abraham","sequence":"additional","affiliation":[{"name":"Christian Medical College; Department of Ophthalmology; Vellore India 632001"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanna","family":"Samuel","sequence":"additional","affiliation":[{"name":"Christian Medical College; Department of Biostatistics; Vellore Tamil Nadu India 632002"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology; 615 North Wolfe Street, W5010 Baltimore Maryland USA 21205"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,2]]},"reference":[{"key":"10.1002\/14651858.CD007920.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Caujolle JP Maschi C Freton A Pages G Gastaud P Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumab injection: preliminary results Ophthalmic Research 2012 57 60","DOI":"10.1159\/000328633"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2125.2008.03278.x","article-title":"Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up","volume":"66","author":"Costagliola","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD007920.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3129\/i09-108","article-title":"Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy","volume":"44","author":"Eid","year":"2009","journal-title":"Canadian Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0004|cit4","unstructured":"Eid T Radwan A el-Menawy W el-Hawary I Outcome of intravitreal bevacizumab (Avastin) followed by aqueous shunting surgery for management of intractable neovascular glaucoma American Academy of Ophthalmology 2008 219"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Georgalas I Koutsandrea C Papaconstantinou D Petrou P Ladas I The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma European Journal of Ophthalmology 2010 251","DOI":"10.1177\/112067211002000144"},{"issue":"3","key":"10.1002\/14651858.CD007920.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/112067210901900318","article-title":"The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma","volume":"19","author":"Gupta","year":"2009","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Jonas JB Golubkina L Libondi T Rensch F Intravitreal bevacizumab for neovascular glaucoma Acta Opthalmologica 2010 e22 3","DOI":"10.1111\/j.1755-3768.2008.01453.x"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Miki A Oshima Y Otori Y Matsushita K Nishida K One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy Eye 2011 658 9","DOI":"10.1038\/eye.2011.58"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0009|cit9","unstructured":"NCT01711879 Use of intravitreal aflibercept injection for neovascular glaucoma clinicaltrials.gov\/ct2\/show\/NCT01711879"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Sedghipour MR Mostafaei A Taghavi Y Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma Clinical Ophthalmology 2011 797 800","DOI":"10.2147\/OPTH.S17896"},{"issue":"4","key":"10.1002\/14651858.CD007920.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5301\/ejo.5000089","article-title":"Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab","volume":"22","author":"Wittstrom","year":"2012","journal-title":"European Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007920.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/IJG.0b013e3181997211","article-title":"Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial","volume":"18","author":"Yazdani","year":"2009","journal-title":"Journal of Glaucoma"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0013|cit13","unstructured":"Arcieri ES Secches DJL Paula JS Barella KA Arcieri RS Jorge R Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed Glaucoma Valve implantation - preliminary report ARVO 2010 627\/A471"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0014|cit14","unstructured":"Chakrabarti M Chakrabarti A Stephen V John SR Efficacy of combining intravitreal bevacizumab monotherapy with panretinal photocoagulation in early stages of neovascular glaucoma American Academy of Ophthalmology 2008 182"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0015|cit15","unstructured":"NCT01128699 Ahmed valve glaucoma implant with adjunctive subconjunctival bevacizumab in refractory glaucoma clinicaltrials.gov\/ct2\/show\/NCT01128699"},{"issue":"22","key":"10.1002\/14651858.CD007920.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007920.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","article-title":"Anti-vascular endothelial growth factor therapy for ocular neovascular disease","volume":"18","author":"Andreoli","year":"2007","journal-title":"Current Opinion in Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007920.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00055735-199904000-00012","article-title":"Glaucoma drainage devices: pros and cons","volume":"10","author":"Assaad","year":"1999","journal-title":"Current Opinion in Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007920.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"issue":"2","key":"10.1002\/14651858.CD007920.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0161-6420(88)33212-4","article-title":"A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy","volume":"95","author":"Blankenship","year":"1988","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007920.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0161-6420(97)30109-2","article-title":"\"Cyclodiode\". Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma","volume":"104","author":"Bloom","year":"1997","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007920.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD007920.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007920.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archopht.125.11.1460","article-title":"Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial","volume":"125","author":"Chang","year":"2007","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0025|cit25","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0161-6420(03)00103-9","article-title":"Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma","volume":"110","author":"Delgado","year":"2003","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007920.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0161-6420(84)34123-9","article-title":"Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy","volume":"91","author":"Doft","year":"1984","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/IAE.0b013e3181679c0b","article-title":"Combination intravitreal bevacizumab\/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma","volume":"28","author":"Ehlers","year":"2008","journal-title":"Retina"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0002-9394(72)91206-8","article-title":"Rubeosis iridis and neovascular glaucoma. Evaluation of cyclocryotherapy","volume":"74","author":"Feibel","year":"1972","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007920.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1442-9071.2007.01667.x","article-title":"Use of antivascular agents for neovascular glaucoma: benefits beyond pressure?","volume":"36","author":"Gandhi","year":"2008","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/jop.2007.0036","article-title":"Role of intravitreal bevacizumab in neovascular glaucoma","volume":"23","author":"Gheith","year":"2007","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD007920.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","article-title":"Intracameral bevacizumab for iris rubeosis","volume":"142","author":"Grisanti","year":"2006","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Grover S Gupta S Sharma R Brar VS Chalam KV Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma British Journal of Ophthalmology 2009 273 4","DOI":"10.1136\/bjo.2008.145714"},{"issue":"4","key":"10.1002\/14651858.CD007920.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00920049","article-title":"Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study","volume":"228","author":"Hayreh","year":"1990","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007920.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000068980","article-title":"Management of central retinal vein occlusion","volume":"217","author":"Hayreh","year":"2003","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0036|cit36","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0037|cit37","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD007920.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma","volume":"142","author":"Iliev","year":"2006","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007920.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0161-6420(95)30874-3","article-title":"Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up","volume":"102","author":"Katz","year":"1995","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12325-008-0047-5","article-title":"Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma","volume":"25","author":"Kitnarong","year":"2008","journal-title":"Advances in Therapy"},{"issue":"12","key":"10.1002\/14651858.CD007920.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00417-006-0321-7","article-title":"Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma","volume":"244","author":"Kiuchi","year":"2006","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007920.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/archophthalmol.2010.350","article-title":"Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series","volume":"129","author":"Kotecha","year":"2011","journal-title":"Archives of Ophthalmology"},{"issue":"9-10","key":"10.1002\/14651858.CD007920.pub2-BIB0043|cit43","first-page":"240","article-title":"Cyclocryocoagulation in treatment of neovascular glaucoma","volume":"126","author":"Kovacic","year":"2004","journal-title":"Lijecnicki Vjesnik"},{"issue":"1","key":"10.1002\/14651858.CD007920.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"American Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007920.pub2-BIB0045|cit45","first-page":"579","article-title":"Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review","volume":"83","author":"Mart\u00ednez-Carpio","year":"2008","journal-title":"Archivos de la Socidad Espanola de Oftalmologia"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0046|cit46","unstructured":"Meyer CF Eter N Holz FG Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial (abstract) Investigative Ophthalmology and Visual Science 2008 E-abstract 273"},{"issue":"2","key":"10.1002\/14651858.CD007920.pub2-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004918.pub2","article-title":"Aqueous shunts for glaucoma","author":"Minckler","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0048|cit48","unstructured":"NCT00406471 Rubeosis anti-VEGF (RAVE) trial for ischemic central retinal vein occlusion clinicaltrials.gov\/ct2\/show\/NCT00406471"},{"issue":"4","key":"10.1002\/14651858.CD007920.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00184005","article-title":"Fluorescein gonioangiography in diabetic neovascularisation","volume":"232","author":"Ohnishi","year":"1994","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007920.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajo.2006.02.015","article-title":"Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy","volume":"142","author":"Oshima","year":"2006","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF01694549","article-title":"Contribution to the teachings of hemorrhagic glaucoma","volume":"17","author":"Pagenstecher","year":"1871","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0052|cit52","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"4","key":"10.1002\/14651858.CD007920.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00006982-198300340-00015","article-title":"Incremental panretinal photocoagulation. Results in treating proliferative diabetic retinopathy","volume":"3","author":"Rogell","year":"1983","journal-title":"Retina"},{"issue":"11","key":"10.1002\/14651858.CD007920.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2337\/diacare.19.11.1306b","article-title":"Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated","volume":"19","author":"Sone","year":"1996","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD007920.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0161-6420(98)92782-8","article-title":"Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma","volume":"105","author":"Tripathi","year":"1998","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007920.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0161-6420(95)30938-4","article-title":"5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study","volume":"102","author":"Tsai","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007920.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/B978-1-4160-0016-7.50216-2","article-title":"Chapter 213: Neovascular Glaucoma","volume-title":"Albert and Jakobiec's Principles and Practice of Ophthalmology","volume":"2","author":"Tsai","year":"2008"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/jop.2009.0036","article-title":"Intravitreal bevacizumab for neovascular glaucoma","volume":"25","author":"Vasudev","year":"2009","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD007920.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ophtha.2006.02.027","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials","volume":"113","author":"D'Amico","year":"2006","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007920.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.ophtha.2008.02.026","article-title":"Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases","volume":"115","author":"Wakabayashi","year":"2008","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007920.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002897.pub2","article-title":"Intraoperative Mitomycin C for glaucoma surgery","author":"Wilkins","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007920.pub2-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001132","article-title":"Postoperative 5-Fluorouracil for glaucoma surgery","author":"Wormald","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007920.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.eye.6702125","article-title":"Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma","volume":"21","author":"Yalvac","year":"2007","journal-title":"Eye"},{"issue":"5","key":"10.1002\/14651858.CD007920.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IJG.0b013e3180457c47","article-title":"Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma","volume":"16","author":"Yazdani","year":"2007","journal-title":"Journal of Glaucoma"},{"issue":"3","key":"10.1002\/14651858.CD007920.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007920","article-title":"Anti-vascular endothelial growth factor for neovascular glaucoma","author":"Simha","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007920.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007920.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T10:28:40Z","timestamp":1716028120000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007920.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,2]]},"references-count":65,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007920.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007920.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,2]]}}}